Dominari Holdings Inc. (NASDAQ:DOMH) Short Interest Update

Posted by Bob Marten on Mar 15th, 2025

Dominari Holdings Inc. (NASDAQ:DOMH – Get Free Report) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 301,300 shares, a drop of 68.4% from the February 13th total of 952,800 shares. Based on an average daily volume of 1,530,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 3.8% of the shares of the company are sold short.

Dominari Stock Down 10.3 %

DOMH traded down $0.54 during midday trading on Friday, reaching $4.71. The company had a trading volume of 1,033,132 shares, compared to its average volume of 2,048,632. Dominari has a 1 year low of $0.83 and a 1 year high of $13.58. The company has a market cap of $51.40 million, a P/E ratio of -1.22 and a beta of 1.08. The business has a 50-day moving average of $4.93 and a two-hundred day moving average of $2.80.

Dominari Dividend Announcement

The company also recently announced a dividend, which was paid on Monday, March 3rd. Shareholders of record on Monday, February 24th were paid a dividend of $0.32 per share. The ex-dividend date was Monday, February 24th.

Institutional Investors Weigh In On Dominari

A hedge fund recently raised its stake in Dominari stock. Renaissance Technologies LLC raised its holdings in shares of Dominari Holdings Inc. (NASDAQ:DOMH – Free Report) by 20.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 56,326 shares of the company’s stock after acquiring an additional 9,400 shares during the quarter. Renaissance Technologies LLC owned approximately 0.89% of Dominari worth $55,000 as of its most recent SEC filing. 42.48% of the stock is owned by institutional investors.

About Dominari

(Get Free Report)

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.